Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Overall cancer mortality rates continue to decrease, new report shows

Overall cancer mortality rates continue to decrease, new report shows

Report investigates clear cell ICC

Report investigates clear cell ICC

Bowel cancer screening test may be less likely to spot cancerous changes in summer: Study

Bowel cancer screening test may be less likely to spot cancerous changes in summer: Study

Data on activity of Nektar's NKTR-102 in gastrointestinal cancer presented at ESMO 12th World Congress

Data on activity of Nektar's NKTR-102 in gastrointestinal cancer presented at ESMO 12th World Congress

Combination of Biothera's Imprime PGG and Erbitux doubles response rate in colorectal cancer patients

Combination of Biothera's Imprime PGG and Erbitux doubles response rate in colorectal cancer patients

Neogenix Oncology's registration statement on Form 10 filed with SEC becomes effective

Neogenix Oncology's registration statement on Form 10 filed with SEC becomes effective

Neogenix Oncology files patent application with USPTO for 16C3 antigen

Neogenix Oncology files patent application with USPTO for 16C3 antigen

Blacks often diagnosed with advanced cancer, more likely to have other underlying health problems

Blacks often diagnosed with advanced cancer, more likely to have other underlying health problems

Survey: 66% of patients with metastatic colorectal cancer are now tested for KRAS

Survey: 66% of patients with metastatic colorectal cancer are now tested for KRAS

ResponseDX: Lung genetic test panel launched to detect EML4-ALK gene variants in lung cancer patients

ResponseDX: Lung genetic test panel launched to detect EML4-ALK gene variants in lung cancer patients

USPTO issues Notice of Allowance for patent application related to Neogenix Oncology's 16C3 antibody

USPTO issues Notice of Allowance for patent application related to Neogenix Oncology's 16C3 antibody

EMA grants Scientific Advice to Aeterna Zentaris for Phase 3 trial of anticancer compound perifosine

EMA grants Scientific Advice to Aeterna Zentaris for Phase 3 trial of anticancer compound perifosine

Ph II data of perifosine + capecitabine in metastatic CRC to be presented at gastrointestinal cancer congress

Ph II data of perifosine + capecitabine in metastatic CRC to be presented at gastrointestinal cancer congress

Aeterna Zentaris receives positive Scientific Advice from EMA for perifosine Phase 3 trial in colorectal cancer

Aeterna Zentaris receives positive Scientific Advice from EMA for perifosine Phase 3 trial in colorectal cancer

Study investigates efficacy of SWV measurement in evaluation of NASH pathophysiology using ultrasound

Study investigates efficacy of SWV measurement in evaluation of NASH pathophysiology using ultrasound

Signature Dx obtains worldwide license to Affymetrix microarray technology for development of CRC tests

Signature Dx obtains worldwide license to Affymetrix microarray technology for development of CRC tests

Scancell, immatics collaborate to develop ImmunoBody vaccines for colorectal cancer

Scancell, immatics collaborate to develop ImmunoBody vaccines for colorectal cancer

Lead researchers develop a novel technique to deliver cancer drugs

Lead researchers develop a novel technique to deliver cancer drugs

TLR4 may provide new strategy for treating patients with PDAC: Study

TLR4 may provide new strategy for treating patients with PDAC: Study

Researchers evaluate outcomes of SD and PD in patients with GISTs

Researchers evaluate outcomes of SD and PD in patients with GISTs

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.